CoreTissue BioEngineering to be first Japanese startup at JPOD @ Boston

CoreTissue BioEngineering Inc., a medical device company developing an artificial ligament derived from decellularised animal tissue, has been accepted into Johnson & Johnson Innovation - JPOD @ Boston. The startup will expand its footprint and accelerate business development in the US through its support team and select key opinion leaders (KOLs). Based in Yokohama, Japan, CoreTissue BioEngineering, Inc. is a spinout company from Waseda University. It has a team of Harvard-trained biomedical scientists, seasoned senior management in medical device development, and experienced clinical research professionals. Following its success in developing artificial ligament for Anterior cruciate ligament (ACL) reconstruction surgery, the startup plans to further apply its technology platform to the development of medical devices for the broader human musculoskeletal system. CoreTissue BioEngineering has already validated a proof-of-concept of the product in an ovine large animal study with a prototype developed using these technologies. The company has received strong backing from the Japanese government, the Japan Agency for Medical Research and Development (AMED) for development from early feasibility through pivotal trials.